Preclinical assessment of suitable natural killer cell sources for chimeric antigen receptor natural killer–based “Off-the-Shelf” acute myeloid leukemia immunotherapies
S Kloess, O Oberschmidt, J Dahlke, XK Vu… - Human Gene …, 2019 - liebertpub.com
The introduction of chimeric antigen receptors (CARs) to augment the anticancer activity of
immune cells represents one of the major clinical advances in recent years. This work …
immune cells represents one of the major clinical advances in recent years. This work …
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based" Off-the-Shelf" Acute Myeloid Leukemia …
S Kloess, O Oberschmidt, J Dahlke… - Human gene …, 2019 - pubmed.ncbi.nlm.nih.gov
The introduction of chimeric antigen receptors (CARs) to augment the anticancer activity of
immune cells represents one of the major clinical advances in recent years. This work …
immune cells represents one of the major clinical advances in recent years. This work …
Preclinical assessment of suitable natural killer cell sources for chimeric antigen receptor natural killer-based" off-the-shelf" acute myeloid leukemia immunotherapies
S Klöß, O Oberschmidt, J Dahlke, XK Vu, C Neudörfl… - 2019 - publica.fraunhofer.de
The introduction of chimeric antigen receptors (CARs) to augment the anticancer activity of
immune cells represents one of the major clinical advances in recent years. This work …
immune cells represents one of the major clinical advances in recent years. This work …
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based" Off-the-Shelf" Acute Myeloid Leukemia …
S Kloess, O Oberschmidt, J Dahlke, XK Vu… - Human Gene …, 2019 - europepmc.org
The introduction of chimeric antigen receptors (CARs) to augment the anticancer activity of
immune cells represents one of the major clinical advances in recent years. This work …
immune cells represents one of the major clinical advances in recent years. This work …